Acinetobacter Baumannii Bacteriophage: Progress in Isolation, Genome Sequencing, Preclinical Research, and Clinical Application

Overview

Journal Curr Microbiol

Specialty Microbiology

Date 2023 Apr 30

PMID 37120784

Authors

Yanqi Li

Shune Xiao

Guangtao Huang

Affiliations

Soon will be listed here.

Abstract

Acinetobacter baumannii (A. baumannii) is a common nosocomial pathogen associated with serious clinical challenges owing to its rapidly increasing resistance to antibiotics. Due to their high host specificity and easy access to the natural environment, bacteriophages (phages) may serve as good antibacterial agents. Phage therapy has been successfully used to treat antibiotic-resistant A. baumannii infections. As a fundamental step before phage therapy, the characterization and sequencing of A. baumannii phages have been well studied. Until October 2022, 132 A. baumannii phages have been sequenced and studied, with their genomes ranging from 4 to 234 kb, and we summarize the characterized and sequenced A. baumannii phages. This review is a current and short overview that does not go into detail on the A. baumannii phages. In addition, preclinical studies and clinical applications of A. baumannii phages are also included.

Citing Articles

Beyond antibiotics: mesenchymal stem cells and bacteriophages-new approaches to combat bacterial resistance in wound infections.

Teymouri S, Yousefi M, Heidari S, Farokhi S, Afkhami H, Kashfi M Mol Biol Rep. 2024; 52(1):64.

PMID: 39699690 DOI: 10.1007/s11033-024-10163-x.

Characterization of bacteriophage vB_AbaS_SA1 and its synergistic effects with antibiotics against clinical multidrug-resistant Acinetobacter baumannii isolates.

Rastegar S, Sabouri S, Tadjrobehkar O, Samareh A, Niaz H, Sanjari N Pathog Dis. 2024; 82.

PMID: 39435653 PMC: 11536755. DOI: 10.1093/femspd/ftae028.

A review of the fighting Acinetobacter baumannii on three fronts: antibiotics, phages, and nanoparticles.

Teymouri S, Pourhajibagher M, Bahador A Mol Biol Rep. 2024; 51(1):1044.

PMID: 39377967 DOI: 10.1007/s11033-024-09979-4.

Isolation and Characterization of Novel Bacteriophages to Target Carbapenem-Resistant .

Choi Y, Kim S, Shin M, Kim J Antibiotics (Basel). 2024; 13(7).

PMID: 39061292 PMC: 11273472. DOI: 10.3390/antibiotics13070610.

Characterization and efficacy against carbapenem-resistant of a novel phage from sewage.

Wang Z, Yang X, Wang H, Wang S, Fang R, Li X Front Cell Infect Microbiol. 2024; 14:1382145.

PMID: 38736748 PMC: 11086170. DOI: 10.3389/fcimb.2024.1382145.

References

Wang X, Loh B, Gordillo Altamirano F, Yu Y, Hua X, Leptihn S . Colistin-phage combinations decrease antibiotic resistance in via changes in envelope architecture. Emerg Microbes Infect. 2021; 10(1):2205-2219. PMC: 8648044. DOI: 10.1080/22221751.2021.2002671. View

Cha K, Oh H, Jang J, Jo Y, Kim W, Ha G . Characterization of Two Novel Bacteriophages Infecting Multidrug-Resistant (MDR) and Evaluation of Their Therapeutic Efficacy . Front Microbiol. 2018; 9:696. PMC: 5932359. DOI: 10.3389/fmicb.2018.00696. View

Shlezinger M, Coppenhagen-Glazer S, Gelman D, Beyth N, Hazan R . Eradication of Vancomycin-Resistant Enterococci by Combining Phage and Vancomycin. Viruses. 2019; 11(10). PMC: 6833023. DOI: 10.3390/v11100954. View

Huang G, Le S, Peng Y, Zhao Y, Yin S, Zhang L . Characterization and genome sequencing of phage Abp1, a new phiKMV-like virus infecting multidrug-resistant Acinetobacter baumannii. Curr Microbiol. 2013; 66(6):535-43. DOI: 10.1007/s00284-013-0308-7. View

Hermoso J, Garcia J, Garcia P . Taking aim on bacterial pathogens: from phage therapy to enzybiotics. Curr Opin Microbiol. 2007; 10(5):461-72. DOI: 10.1016/j.mib.2007.08.002. View

Tan X, Chen H, Zhang M, Zhao Y, Jiang Y, Liu X . Clinical Experience of Personalized Phage Therapy Against Carbapenem-Resistant Lung Infection in a Patient With Chronic Obstructive Pulmonary Disease. Front Cell Infect Microbiol. 2021; 11:631585. PMC: 7952606. DOI: 10.3389/fcimb.2021.631585. View

Zhang L, Wang X, Hua X, Yu Y, Leptihn S, Loh B . Therapeutic evaluation of the Acinetobacter baumannii phage Phab24 for clinical use. Virus Res. 2022; 320:198889. DOI: 10.1016/j.virusres.2022.198889. View

Manohar P, Madurantakam Royam M, Loh B, Bozdogan B, Nachimuthu R, Leptihn S . Synergistic Effects of Phage-Antibiotic Combinations against . ACS Infect Dis. 2022; 8(1):59-65. DOI: 10.1021/acsinfecdis.1c00117. View

Hua Y, Luo T, Yang Y, Dong D, Wang R, Wang Y . Phage Therapy as a Promising New Treatment for Lung Infection Caused by Carbapenem-Resistant in Mice. Front Microbiol. 2018; 8:2659. PMC: 5767256. DOI: 10.3389/fmicb.2017.02659. View

10.

Kusradze I, Karumidze N, Rigvava S, Dvalidze T, Katsitadze M, Amiranashvili I . Characterization and Testing the Efficiency of Phage as an Antibacterial Agent. Front Microbiol. 2016; 7:1590. PMC: 5047890. DOI: 10.3389/fmicb.2016.01590. View

11.

Badawy S, Pajunen M, Haiko J, Baka Z, Abou-Dobara M, El-Sayed A . Identification and Functional Analysis of Temperate Siphoviridae Bacteriophages of . Viruses. 2020; 12(6). PMC: 7354433. DOI: 10.3390/v12060604. View

12.

Turner D, Ackermann H, Kropinski A, Lavigne R, Sutton J, Reynolds D . Comparative Analysis of 37 Bacteriophages. Viruses. 2018; 10(1). PMC: 5795418. DOI: 10.3390/v10010005. View

13.

Gordillo Altamirano F, Forsyth J, Patwa R, Kostoulias X, Trim M, Subedi D . Bacteriophage-resistant Acinetobacter baumannii are resensitized to antimicrobials. Nat Microbiol. 2021; 6(2):157-161. DOI: 10.1038/s41564-020-00830-7. View

14.

Aleshkin A, Ershova O, Volozhantsev N, Svetoch E, Popova A, Rubalskii E . Phagebiotics in treatment and prophylaxis of healthcare-associated infections. Bacteriophage. 2017; 6(4):e1251379. PMC: 5221749. DOI: 10.1080/21597081.2016.1251379. View

15.

Sarhan W, Azzazy H . Phage approved in food, why not as a therapeutic?. Expert Rev Anti Infect Ther. 2014; 13(1):91-101. DOI: 10.1586/14787210.2015.990383. View

16.

Peleg A, Seifert H, Paterson D . Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008; 21(3):538-82. PMC: 2493088. DOI: 10.1128/CMR.00058-07. View

17.

Yin S, Huang G, Zhang Y, Jiang B, Yang Z, Dong Z . Phage Abp1 Rescues Human Cells and Mice from Infection by Pan-Drug Resistant Acinetobacter Baumannii. Cell Physiol Biochem. 2017; 44(6):2337-2345. DOI: 10.1159/000486117. View

18.

Burmeister A, Fortier A, Roush C, Lessing A, Bender R, Barahman R . Pleiotropy complicates a trade-off between phage resistance and antibiotic resistance. Proc Natl Acad Sci U S A. 2020; 117(21):11207-11216. PMC: 7260982. DOI: 10.1073/pnas.1919888117. View

19.

Moye Z, Woolston J, Sulakvelidze A . Bacteriophage Applications for Food Production and Processing. Viruses. 2018; 10(4). PMC: 5923499. DOI: 10.3390/v10040205. View

20.

Grygorcewicz B, Wojciuk B, Roszak M, Lubowska N, Blazejczak P, Jursa-Kulesza J . Environmental Phage-Based Cocktail and Antibiotic Combination Effects on Biofilm in a Human Urine Model. Microb Drug Resist. 2020; 27(1):25-35. DOI: 10.1089/mdr.2020.0083. View